Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03541603 · ClinicalTrials.gov registry record · Phase 2
Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF
A Phase 2 study, sponsored by Tenax Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
NCT03541603 is a Phase 2 study that has completed, run by Tenax Therapeutics. The registered enrollment target is 44 participants.
The verdict
NCT03541603, a Phase 2 study, has completed, sponsored by Tenax Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
Study Summary
Phase 2 study to evaluate the efficacy and safety of intermittent levosimendan compared with placebo in hemodynamic improvement with exercise in PH-HFpEF subjects
Interventions
- DRUG Matching Placebo
- DRUG Levosimendan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2018-11-14 |
| Est. Completion | 2020-04-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03541603
The ClinicalTrials.gov registry entry for NCT03541603 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tenax Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Matching Placebo is the first listed.
NCT03541603 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03541603 about?
NCT03541603 is a clinical study titled "Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF". Phase 2 study to evaluate the efficacy and safety of intermittent levosimendan compared with placebo in hemodynamic improvement with exercise in PH-HFpEF subjects
What is the current status of trial NCT03541603?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2018-11-14. Estimated completion is 2020-04-07.
What interventions are being tested in trial NCT03541603?
The interventions under investigation include: Matching Placebo (DRUG), Levosimendan (DRUG).
Who is sponsoring clinical trial NCT03541603?
This trial is sponsored by Tenax Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.